Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. is an oncology therapeutics company dedicated to developing advanced antibody-drug conjugate (ADC) therapies to provide improved cancer treatments. The company's mission involves applying advanced technologies to established tumor biology to efficiently deliver these therapies. Whitehawk Therapeutics is headquartered in Morristown, New Jersey, United States.

The company's core offerings include a portfolio of three next-generation antibody-drug conjugate (ADC) candidates: HWK-007, HWK-016, and HWK-206. These ADCs are designed to target clinically validated proteins such as PTK7 (HWK-007), MUC16 (HWK-016), and SEZ6 (HWK-206), which are broadly expressed in high-potential cancer indications, including lung and gynecological cancers. Whitehawk's ADC assets are engineered to overcome the limitations of first-generation ADCs by focusing on enhanced efficacy and safety, utilizing technology in-licensed from WuXi Biologics and Hangzhou DAC.

Whitehawk Therapeutics is a clinical-stage company with HWK-007 and HWK-016 actively recruiting for Phase 1 trials. An Investigational New Drug (IND) submission for HWK-206 is planned for mid-2026, with a Phase 1 trial expected to commence in Q3 2026. Dave Lennon, PhD, serves as the President and CEO, having been appointed in October 2023. In December 2025, Margaret Dugan, MD, was appointed as Chief Medical Officer. The company completed a strategic transformation in March 2025 by divesting its Aadi subsidiary to Kaken Pharmaceuticals, thereby sharpening its focus entirely on its ADC pipeline. Whitehawk Therapeutics recently presented comprehensive preclinical data highlighting its next-generation ADC portfolio at the AACR 2026 meeting in April 2026.